Delving into the Latest Updates on Ceforanide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ceforanide (USP/INN), BL-S786, NSC-760049

+ [2]

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesCardiovascular DiseasesDigestive System Disorders+ [4]

Active Indication

Bone and joint infectionsEndocarditisInfections of musculoskeletal system+ [7]

Inactive Indication

Bacterial InfectionsSurgical Wound Infection

Originator Organization

Bristol Myers Squibb Co.

Active Organization

China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute

Jiangsu Sinoya Biomedical Technology Co., Ltd.

Inactive Organization

Bristol Laboratories Ltd.

License Organization-

Drug Highest PhasePhase 1

First Approval Date

United States (24 May 1984),

Bacterial InfectionsSurgical Wound Infection

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC20H21N7O6S2

InChIKeySLAYUXIURFNXPG-CRAIPNDOSA-N

CAS Registry60925-61-3

拟在健康受试者中进行注射用头孢雷特单次和多次给药人体药动学研究。评价健康受试者单次和多次静脉输注注射用头孢雷特的耐受性及安全性，计算主要药动学参数，评价单次和多次静脉输注注射用头孢雷特后受试者体内的药动学特征；同时考察尿药排泄情况。

[Translation]

It is planned to conduct a single and multiple dose human pharmacokinetic study of Cefuroxime for Injection in healthy subjects. The tolerability and safety of single and multiple intravenous infusions of Cefuroxime for Injection in healthy subjects will be evaluated, the main pharmacokinetic parameters will be calculated, and the pharmacokinetic characteristics of Cefuroxime for Injection in subjects after single and multiple intravenous infusions will be evaluated; at the same time, the urinary excretion of the drug will be investigated.

Start Date-

Sponsor / Collaborator

China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute

[+1]

100 Clinical Results associated with Ceforanide

Login to view more data

100 Translational Medicine associated with Ceforanide

Login to view more data

100 Patents (Medical) associated with Ceforanide

Login to view more data

188

Literatures (Medical) associated with Ceforanide

01 Mar 2025·Evolutionary Bioinformatics

Structural and Functional Characterization of a Putative Type VI Secretion System Protein in Cronobacter sakazakii as a Potential Therapeutic Target: A Computational Study

Article

Author: Rahman, Md Habibur ; Akter, Nurun Nahar ; Hossain, Md. Arju ; Asha, Israt Jahan ; Uddin, Md. Moin ; Uddin, Nesar ; Uddin, Md Soyeb ; Alam, Fahadul ; Zihad, Md. Abu ; Shifat, Siratul Kubra

Background::

Cronobacter sakazakii , a foodborne pathogen with a fatality rate of 33%, is a rod-shaped, Gram-negative, non-spore-forming bacterium responsible for causing meningitis, bacteremia, and necrotizing enterocolitis. Despite many unknown functions of hypothetical proteins in bacterial genomes, bioinformatic techniques have successfully annotated their roles in various pathogens.

Objectives::

The aim of this investigation is to identify and annotate the structural and functional properties of a hypothetical protein (HP) from Cronobacter sakazakii 7G strain (accession no. WP_004386962.1, 277 residues) using computational tools.

Methods::

Multiple bioinformatic tools were used to identify the homologous protein and to construct and validate its 3D structure. A 3D model was generated using SWISS-MODEL and validated using tools, developing a reliable 3D structure. The STRING and CASTp servers provided information on protein-protein interactions and active sites, identifying functional partners.

Results::

The putative protein was soluble, stable, and localized in the cytoplasmic membranes, indicating its biological activity. Functional annotation identified TagJ (HsiE1) within the protein, a member of the ImpE superfamily involved in the transport of toxins and a part of the bacterial type VI secretion system (T6SS). The 3-dimensional structure of this protein was validated through molecular docking involving 6 different compounds. Among these, ceforanide demonstrated the strongest binding scores, -7.5 kcal/mol for the hypothetical protein and −7.2 kcal/mol for its main template protein (PDB ID: 4UQX.1).

Conclusion::

Comparative genomics study suggests that the protein found in C. sakazakii may be a viable therapeutic target because it seems distinctive and different from human proteins. The results of multiple sequence alignment (MSA) and molecular docking supported HP’s potential involvement as a T6SS. These in silico results represent that the examined HP could be valuable for studying C. sakazakii infections and creating medicines to treat C. sakazakii -mediated disorders.

01 Mar 2025·PHARMACEUTICAL CHEMISTRY JOURNAL

Prediction of the Drug’s Clearance Correlation Between Humans and Rats

Author: Shayanfar, Ali ; Navaei, Kiana Shabani

Animal species, i.e. rats, are used to evaluate a drugs biol. activity and pharmacokinetics, such as clearance.This study aims to develop a predictive method to evaluate the relationship between the clearance of drugs in rats and humans.Adataset of 395 drugs composed of human and rat clearance data was applied in this study.The drugs, according to the clearance differences, were divided into two groups on the basis of the correlation between humans and rats.Structural parameters were used to develop a model to estimate the class of each drug by binary logistic regression.The results showed that the developed models are a useful way to show which drug have an acceptable correlation between human and rat clearance by using structural features.They can be used to determine the group of drugs with an accuracy of 74%.According to the validation results, the developed method has an acceptable accuracy for checking the relationship between the clearance of drugs in humans and rats.This modeling can be used to exclude the drugs from experiments in rats which reveal a considerable difference between the clearance of humans and that of rats.

01 Jun 2023·Food chemistry: X

Proteomics and metabolomics profiling of meat exudate to determine the impact of postmortem aging on oxidative stability of beef muscles

Article

Author: Thimmapuram, Jyothi ; Aryal, Uma K ; Xie, Shaojun ; Kim, Yuan H Brad ; Setyabrata, Derico ; Ma, Danyi ; Cooper, Bruce R

The objective of this study was to characterize the major proteomes and metabolites in beef exudate and determine their relationship to color and oxidative quality of beef muscles. Beef loin (LD) and tenderloin (PM) muscles were cut into sections, individually vacuum-packaged, and aged for 9, 16 and 23 days at 2 °C. Following aging, beef exudates were collected and analyzed for both proteomics and metabolomics profiles. Proteome analysis indicated clustering by muscle types, while metabolomics profiling further clustered the samples based on the aging periods. The PM exudate had a greater concentration of oxidative enzymes, while the LD exudate contained more glycolytic enzymes. Greater lipid, nucleotide, carnitine and glucoside metabolites were observed in LD and 23d exudates. HSP70 and laminin proteins, together with glucosides metabolites, were correlated to muscle oxidative stability. The results indicated that meat exudate could be a viable analytical matrix to determine changes in quality attributes of meat with aging.

100 Deals associated with Ceforanide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00259	Ceforanide	J01DC11	DB00923

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	United States	Bristol Laboratories Ltd.	24 May 1984
Surgical Wound Infection	United States	Bristol Laboratories Ltd.	24 May 1984

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bone and joint infections	Phase 1	China	Jiangsu Sinoya Biomedical Technology Co., Ltd.	27 Aug 2018
Bone and joint infections	Phase 1	China	China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute	27 Aug 2018
Endocarditis	Phase 1	China	China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute	27 Aug 2018
Endocarditis	Phase 1	China	Jiangsu Sinoya Biomedical Technology Co., Ltd.	27 Aug 2018
Infections of musculoskeletal system	Phase 1	China	China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute	27 Aug 2018
Infections of musculoskeletal system	Phase 1	China	Jiangsu Sinoya Biomedical Technology Co., Ltd.	27 Aug 2018
Peritonitis	Phase 1	China	China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute	27 Aug 2018
Peritonitis	Phase 1	China	Jiangsu Sinoya Biomedical Technology Co., Ltd.	27 Aug 2018
Pyelonephritis	Phase 1	China	China Medicine Group General Company Sichuan Bacteriophage Industry Research Institute	27 Aug 2018
Pyelonephritis	Phase 1	China	Jiangsu Sinoya Biomedical Technology Co., Ltd.	27 Aug 2018